Evidence-Based Complementary and Alternative Medicine

Review Article

Effectiveness and Safety of Compound Chinese Medicine plus Routine Western Medicine in In-Stent Restenosis: A Meta-Analysis and Systematic Review

Table 1

Baseline characteristics of included patients.


Author, Year	No. of patients (EG/CG)	Age, mean (SD/range), EG/CG, year	Gender, M/F, N.	Co-morbidities, N. EG/CG	Lesion site, EG/CG	Lesion number, EG/CG	Stent number, EG/CG	CAD diagnostic guidelines

DAI GF 2017	117 (57/60)	63.5 (9.82) 65.07/(8.99)	E: 36/21 C39/21	HTN: 40/41 DM: 33/34 Dyslipidaemia: 49/51	LMCA: 4/3 LAD: 12/13 LCX: 9/10 RAC: 10/11	DBL: 15/16 TBL: 4/5 MBL: 3/2	109/112	CA

ZHANG RZ 2017	138 (70/68)	59.4 (8.5)/57.3 (6.4)	E: 41/29 C: 40/28	HTN: 14/13 DM: 10/9 Hyperlipidemia: 12/10	NR	NR	NR	2007: Guideline for Percutaneous Coronary Intervention (CSC)

WANG KL 2016	62 (32/30)	58.93 (5.52)/60.43 (5.39)	E: 22/10 C: 16/14	HTN: 25/23 DM: 8/9 Hyperlipidemia: 11/13	NR	SBL: 9/8 TBL: 17/15 TBL: 6/8	1.83 ± 0.58/1.98 ± 0.70	CA

GONG XY 2016	92 (46/46)	57.8 (1.9)/57.5 (2.1)	E: 21/25 C: 20/26	NR	NR	NR	NR	Nomenclature and diagnostic criteria of Ischemic heart disease (WHO)

TANG YY 2016	64 (32/32)	52.32 (4.12)/53.53 (4.55)	E: 20/12 C: 22/10	HTN: 20/19 DM: 19/17 Hyperlipidemia: 25/24	NR	NR	NR	CA

ZHOU JC 2016	68 (34/34)	NR	NR	NR	NR	NR	NR	Nomenclature and diagnostic criteria of Ischemic heart disease (WHO)

ZHU HB 2016	64 (32/32)	61.5 (5.5)/60.5 (5.8)	E: 19/13 C: 18/14	NR	NR	NR	NR	Nomenclature and diagnostic criteria of Ischemic heart disease (WHO)

XIAO NH 2016	120 (60/60)	63.15 (9.45)/63.83 (9.50)	E: 40/20 C: 39/21	HTN: 44/43 DM: 14/18	NR	SBL: 18/19 TBL: 20/19 TBL: 22/22	137/150	CA
REN DD 2016	60 (30/30)	55.4 (9.78)/55.76 (9.25)	E: 16/14 C: 18/12	HTN: 14/13 DM: 4/5	NR	SBL: 16/17 TBL: 10/9 TBL: 4/4	48/47	CA

LI QZ 2016	68 (34/34)	60.2 (4.3)/61.3 (5.2)	E: 20/14 C: 19/15	NR	NR	NR	NR	Nomenclature and diagnostic criteria of Ischemic heart disease (WHO)

SUN QY 2016	88 (44/44)	63.1 (3.2)/62.5 (2.6)	E: 29/15 C: 28/16	HTN: 19/18 DM: 10/9 Hyperlipidemia: 13/14	NR	NR	NR	CA

XU MT 2016	72 (36/36)	58.2 (4.5)/60.5 (10.5)	E: 21/15 C: 20/15	NR	NR	NR	NR	Nomenclature and diagnostic criteria of Ischemic heart disease (WHO)

MENG XL 2016	60 (30/30)	60 (46~72)/61.5 (49~73)	E: 16/14 C: 13/17	HTN: 12/10 DM: 5/5 Arrhythmia: 8/9	NR	NR	NR	⟪Internal medicine⟫

YANG TL 2016	343 (172/171)	57.93 (9.77)/58.63 (10.27)	E: 137/35 C: 134/37	HTN: 105/102 DM: 172/171	LMCA: 6/7 LAD: 117/111 LCX: 101/92 RAC: 77/88	SBL: 66/69 DBL: 86/77 MBL: 23/25	301/298	CA

WANG X 2016	128 (64/64)	65.8 (4.4)/65.3 (4.2)	E: 49/15 C: 48/16	NR	NR	SBL: 26/25 DBL: 23/22 MBL: 16/17	NR	⟪Practice of internal medicine⟫
ZHOU W 2015	100 (50/50)	69.08 (7.46)/69.46 (7.35)	E: 28/22 C: 27/23	HTN: 23/24 DM: 9/10 Hyperlipidemia: 20/19	NR	NR	NR	2009: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction and ACC/AHA/SCAI guidelines on percutaneous coronary intervention.

PENG WD 2015	64 (32/32)	61.5 (5.5)/60.5 (5.8)	E: 19/13 C: 18/14	NR	NR	NR	NR	Nomenclature and diagnostic criteria of Ischemic heart disease (WHO)

ZHANG Y 2015	80 (40/40)	53.2 (5.4)/51.9 (5.3)	E: 21/19 C: 22/18	NR	NR	NR	NR	CA

WANG K 2015	148 (75/73)	57.6 (10.3)/56.5 (9.1)	E: 59/16 C: 56/19	HTN: 32/34 DM: 23/28 Hyperlipidemia: 55/45	NR	NR	NR	CA

LU HW 2014	180 (90/90)	60.2 (6.9)/61.8 (7.2)	E: 48/42 C: 46/44	HTN: 59/53 DM: 23/25 Hyperlipidemia: 13/17	NR	SBL: 36/32 DBL: 33/40 TBL: 21/18	132/127	Nomenclature and diagnostic criteria of Ischemic heart disease (WHO), 2009: Guideline for Percutaneous Coronary Intervention (CSC)

ZHANG PF 2014	123 (61/62)	57.44 (8.07)/60.64 (8.91)	E: 39/22 C: 38/24	NR	NR	NR	NR	CA

SHI QJ 2014	60 (30/30)	60.3 (6.2)/62.8 (6.2)	E: 20/10 C: 18/12	NR	NR	NR	NR	Nomenclature and diagnostic criteria of Ischemic heart disease (WHO)

CHEN K 2014	80 (40/40)	56.2 (5.2)/57.9 (5.3)	E: 19/21 C: 20/20	NR	NR	NR	NR	CA
LI B 2014	102 (51/51)	61.2 (5.8)/60.6 (5.8)	E: 38/17 C: 36/19	HTN: 22/24 DM: 10/11 Hyperlipidemia: 30/25	NR	NR	77/81	CA

LI CW 2014	83 (43/40)	53.14 (9.45)/54.19 (10.7)	E: 27/16 C: 22/18	NR	NR	NR	NR	2007: Guideline for Percutaneous Coronary Intervention (CSC)

WANG ZQ 2013	100 (50/50)	56.92 (12.21)/58.90 (13.19)	E:28/22 C:27/23	HTN: 14/16 DM: 8/9 Hyperlipidemia: 12/11	NR	SBL: 12/10	NR	Nomenclature and diagnostic criteria of Ischemic heart disease (WHO)

ZHANG Q 2013	1123 (509/514)	55.6 ± 7.9/55.5 ± 7.8	E: 438/71 C: 441/73	HTN: 274/29 DM: 139/127 Stroke: 3/26	NR	NR	NR	Nomenclature and diagnostic criteria of Ischemic heart disease (WHO)

DENG XD 2013	62 (31/30)	59.0 (42~76)/59.5 (41~78)	E: 21/10 C: 20/10	NR	LAD: 20/18 LCX: 2/1 RAC: 9/11	NR	NR	Nomenclature and diagnostic criteria of Ischemic heart disease (WHO)

CHEN K 2013	60 (30/30)	55.2 (5.2)/54.9 (5.3)	E: 16/14 C: 15/15	NR	NR	NR	NR	CA

SI XC 2013	120 (60/60)	NR	NR	NR	NR	NR	NR	Nomenclature and diagnostic criteria of Ischemic heart disease (WHO)

HAN P 2012	102 (54/48)	NR	NR	NR	NR	NR	NR	CA

REN XY 2012	68 (35/33)	56.2 (5.3)/55.9 (5.8)	E: 18/17 C: 17/16	NR	NR	NR	NR	Nomenclature and diagnostic criteria of Ischemic heart disease (WHO)

NIU XY 2012	71 (41/30)	60.5 (6.50)/61.8 (6.1)	E: 25/16 C: 18/12	NR	NR	NR	NR	Nomenclature and diagnostic criteria of Ischemic heart disease (WHO)

GAO XX 2012	60 (30/30)	56.5 (5.3)/55.9 (5.8)	E: 16/14 C: 15/15	HTN: 9/11 DM: 11/10	NR	NR	NR	CA
DAI GF 2011	61 (31/30)	61.3 (7.23)/63.5 (6.1)	E: 19/12 C: 17/13	NR	NR	NR	NR	Nomenclature and diagnostic criteria of Ischemic heart disease (WHO) 1979

MEI CL 2011	124 (61/63)	56.3 (5.6)/58.3 (6.1)	E: 35/26 C: 36/27	DM: 16/17 HTN: 20/23	NR	NR	NR	Nomenclature and diagnostic criteria of Ischemic heart disease (WHO)

WANG XD 2010	132 (68/64)	65.2 (9.9)/65.1 (10.4)	T: 43/25 C: 45/19	HTN: 59/61 DM: 68/64 Hyperlipidemia: 52/49	LAD: 36/34 LCX: 33/26 RAC: 26/28	SBL: 32/26 DBL: 34/35 TBL: 2/3	131/126	CA

CHENG SJ 2010	60 (30/30)	57.9 (5.2)/58.1 (3.9)	T: 20/10 C: 22/8	HTN: 16/13 DM: 6/9 hyperlipidemia: 12/11	NR	SBL: 19/23 MBL: 11/7	NR	Nomenclature and diagnostic criteria of Ischemic heart disease (WHO)

DAI GF 2010	94 (49/45)	61.2 (6.3)/63.8 (5.9)	T: 38/21 C: 26/20	NR	NR	NR	NR	Nomenclature and diagnostic criteria of Ischemic heart disease (WHO)

LIU LL 2010	60 (30/30)	63.57 (50~75)/62.8 (50~68)	T: 19/11 C: 18/12	HTN: 22/19 DM: 12/14 Hyperlipidemia: 5/6	NR	NR	NR	2007: Guideline for Percutaneous Coronary Intervention (CSC)

EG = experimental group; CG = control group; SD = standard deviation; M/F = male/female; N = number of subjects; CAD = coronary artery disease; HTN = hypertension; DM = diabetes mellitus; LMCA = left main coronary artery; LAD = left anterior descending coronary; LCX = left circumflex; RAC = right coronary artery; DBL = double branch Lesions; TBL = three branch Lesions; MBL = multiple branch lesions; CA = coronary angiography; NR = not reported; CSC = Chinese Society of Cardiology; WHO = World Health Organization; SBL: Single branch Lesion; ACC = American College of Cardiology; AHA = American Heart Association; SCAI, Society for Cardiovascular Angiography and Interventions.